Michael DesJardin
Chief Tech/Sci/R&D Officer presso HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Profilo
Attualmente, Michael A. DesJardin occupa la posizione di Executive VP-Technical Operations & Quality presso Horizon Therapeutics Plc e Senior Vice President-Technical Operations presso Horizon Pharmaceutical LLC (una filiale di Horizon Therapeutics Plc). È anche vicepresidente senior delle operazioni tecniche presso la Horizon Pharmaceutical LLC. In precedenza ha ricoperto la posizione di vicepresidente senior-sviluppo del prodotto presso Jazz Pharmaceuticals Plc e di direttore esecutivo-ricerca e sviluppo degli impianti presso ALZA Corp. Il signor DesJardin si è laureato alla University of California, Berkeley.
Posizioni attive di Michael DesJardin
| Società | Posizione | Inizio |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 01/02/2017 |
Precedenti posizioni note di Michael DesJardin
| Società | Posizione | Fine |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Chief Tech/Sci/R&D Officer | 01/10/2016 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/03/2015 |
| ALZA CORPORATION | Chief Tech/Sci/R&D Officer | - |
Formazione di Michael DesJardin
| University of California, Berkeley | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Aziende private | 3 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
- Borsa valori
- Insiders
- Michael DesJardin
